Follow
LUZALBA DEL CARMEN SANOJA FLORES
LUZALBA DEL CARMEN SANOJA FLORES
Unknown affiliation
Verified email at usal.es
Title
Cited by
Cited by
Year
Next Generation Flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma
J Flores-Montero, L Sanoja-Flores, B Paiva, N Puig, O García-Sánchez, ...
Leukemia 31 (10), 2094-2103, 2017
5822017
Immunophenotype of normal vs. myeloma plasma cells: Toward antibody panel specifications for MRD detection in multiple myeloma
J Flores‐Montero, R de Tute, B Paiva, JJ Perez, S Böttcher, H Wind, ...
Cytometry Part B: Clinical Cytometry 90 (1), 61-72, 2016
2442016
Measurable residual disease by next-generation flow cytometry in multiple myeloma
B Paiva, R Martinez-Martinez, R Maldonado, A Sureda, R Garcia-Sanz, ...
J. Clin. Oncol., 2020
2092020
Next generation flow for minimally-invasive blood characterization of MGUS and multiple myeloma at diagnosis based on circulating tumor plasma cells (CTPC)
L Sanoja-Flores, J Flores-Montero, JJ Garcés, B Paiva, N Puig, ...
Blood cancer journal 8 (12), 117, 2018
912018
Blood monitoring of circulating tumor plasma cells by next generation flow in multiple myeloma after therapy
L Sanoja-Flores, J Flores-Montero, N Puig, T Contreras-Sanfeliciano, ...
Blood, The Journal of the American Society of Hematology 134 (24), 2218-2222, 2019
852019
Utility of CD 54, CD 229, and CD 319 for the identification of plasma cells in patients with clonal plasma cell diseases
F Pojero, J Flores‐Montero, L Sanoja, JJ Pérez, N Puig, B Paiva, ...
Cytometry Part B: Clinical Cytometry 90 (1), 91-100, 2016
712016
Transcriptional profiling of circulating tumor cells in multiple myeloma: a new model to understand disease dissemination
JJ Garcés, M Simicek, M Vicari, L Brozova, L Burgos, R Bezdekova, ...
Leukemia 34 (2), 589-603, 2020
482020
Circulating tumor cells for the staging of patients with newly diagnosed transplant-eligible multiple myeloma
JJ Garcés, MT Cedena, N Puig, L Burgos, JJ Perez, L Cordon, ...
Journal of Clinical Oncology 40 (27), 3151-3161, 2022
472022
Fluorochrome choices for multi-color flow cytometry
J Flores-Montero, T Kalina, A Corral-Mateos, L Sanoja-Flores, ...
Journal of immunological methods 475, 112618, 2019
462019
GEM (Grupo Español de Mieloma)/PETHEMA (Programa Para el Estudio de la Terapéutica en Hemopatías Malignas) Cooperative Study Group. Measurable residual disease by next …
B Paiva, N Puig, MT Cedena, L Rosiñol, L Cordón, MB Vidriales, L Burgos, ...
J Clin Oncol 38 (8), 784-792, 2020
262020
Detection of circulating tumor plasma cells in monoclonal gammopathies: methods, pathogenic role, and clinical implications
L Sanoja-Flores, J Flores-Montero, M Pérez-Andrés, N Puig, A Orfao
Cancers 12 (6), 1499, 2020
232020
Selection and validation of antibody clones against IgG and IgA subclasses in switched memory B-cells and plasma cells
E Blanco, M Perez-Andres, L Sanoja-Flores, M Wentink, O Pelak, ...
Journal of Immunological Methods 475, 112372, 2019
212019
Reference values to assess hemodilution and warn of potential false-negative minimal residual disease results in myeloma
N Puig, J Flores-Montero, L Burgos, MT Cedena, L Cordón, JJ Pérez, ...
Cancers 13 (19), 4924, 2021
132021
Monocyte subsets and serum inflammatory and bone-associated markers in monoclonal gammopathy of undetermined significance and multiple myeloma
D Damasceno, J Almeida, C Teodosio, L Sanoja-Flores, A Mayado, ...
Cancers 13 (6), 1454, 2021
132021
Next generation flow (NGF): A high sensitive technique to detect circulating peripheral blood (PB) clonal plasma cells (cPC) in patients with newly diagnosed of plasma cell …
L Sanoja-Flores, B Paiva, JA Flores-Montero, N Puig, L Burgos, O García, ...
Blood, The Journal of the American Society of Hematology 126 (23), 4180-4180, 2015
102015
Monitoring of kinetics and exhaustion markers of circulating CAR-T cells as early predictive factors in patients with B-cell malignancies
CB García-Calderón, B Sierro-Martínez, E García-Guerrero, ...
Frontiers in Immunology 14, 1152498, 2023
92023
B-cell regeneration profile and minimal residual disease status in bone marrow of treated multiple myeloma patients
R Mendonça de Pontes, J Flores-Montero, L Sanoja-Flores, N Puig, ...
Cancers 13 (7), 1704, 2021
82021
Plasma cell disorders
J Flores-Montero, L Sanoja, JJ Pérez, F Pojero, N Puig, MB Vidriales, ...
Manual of Molecular and Clinical Laboratory Immunology, 235-250, 2016
42016
Reference values to assess hemodilution and warn of potential false-negative minimal residual disease results in myeloma. Cancers. 2021; 13
N Puig, J Flores-Montero, L Burgos, MT Cedena, L Cordon, JJ Perez, ...
s Note: MDPI stays neutral with regard to jurisdictional claims in published …, 2021
32021
Non-invasive genetic profiling is highly applicable in multiple myeloma (MM) through characterization of circulating tumor cells (CTCs)
L Burgos, D Alignani, JJ Garces, L Ortiz, T Jelinek, V Segura, L Sanoja, ...
Blood 128 (22), 801, 2016
32016
The system can't perform the operation now. Try again later.
Articles 1–20